Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Clin Exp Immunol ; 184(3): 332-7, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26749258

ABSTRACT

Selective immunoglobulin A (IgA) deficiency (IgAD) is the most common primary immunodeficiency in the western world. The aim of the study was to investigate the prevalence and clinical characteristics of Helicobacter pylori-infected dyspeptic patients with IgAD. Case samples were drawn from all subjects ≥ 12 years of age (n = 104729) who had undergone serum total IgA measurements during 2004-14 for any reason at Leumit Healthcare Services (Israel) and had serum total IgA < 0·07 g/l. The control group was comprised of a random sample of remaining patients with a case-control ratio of 10 controls for each case. The dyspeptic diseases were identified and retrieved from Leumit Health Care Services electronic database using specific ICD-9-CM diagnostic codes. The case group included 347 subjects and the control group 3470 subjects. There were no significant differences in the prevalence of patients with dyspepsia [84 (24·2%) versus 821 (23·6%) for cases and controls, respectively]. Additionally, there was no difference in a proportion of dyspeptic H. pylori-positive subjects [59 (17·1%) versus 524 (15·1%)] between the case and control groups. Only 59 (17%) among the 347 IgAD patients underwent gastroscopy. A significantly larger proportion of case subjects experienced several forms of gastritis [13 (61·9%) versus 38 (21·6%), P < 0·001), duodenal ulcers [seven (33·3%) versus 19 (10·8%); P = 0·01] and nodular lymphoid hyperplasia (NLH) [two (9·5%) versus none; P = 0·011]. IgAD is not associated with increased prevalence of H. pylori-associated dyspepsia; nevertheless, H. pylori-infected dyspeptic IgAD subjects experience more EGD-proved gastritis, duodenal ulcers and NLH.


Subject(s)
Castleman Disease/diagnosis , Duodenal Ulcer/diagnosis , Dyspepsia/diagnosis , Gastritis/diagnosis , Helicobacter Infections/diagnosis , IgA Deficiency/diagnosis , Adolescent , Adult , Aged , Case-Control Studies , Castleman Disease/complications , Castleman Disease/immunology , Child , Databases, Factual , Duodenal Ulcer/complications , Duodenal Ulcer/immunology , Dyspepsia/immunology , Electronic Health Records , Gastritis/complications , Gastritis/immunology , Helicobacter Infections/complications , Helicobacter Infections/immunology , Helicobacter pylori/growth & development , Helicobacter pylori/immunology , Humans , IgA Deficiency/complications , IgA Deficiency/immunology , Immunoglobulin A/blood , Israel , Middle Aged
2.
Arch Dermatol Res ; 306(1): 67-74, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23591742

ABSTRACT

Rituximab has recently been reported in retrospective studies to be effective in pemphigus at the dosing schedule used for treating rheumatoid arthritis (RA) of two 1,000 mg infusions 2 weeks apart. While the effect of rituximab on B cells has been well described, its effect on global T cell function has not been assessed. Ten patients who received RA dosage rituximab were prospectively assessed for clinical response. Immunological response including autoantibody titers, CD20+ B cell, and CD4+ T cell counts was assessed pre- and post-treatment. The CD4+ T cell function was determined by a novel assay measuring intracellular ATP levels in response to mitogenic stimulus. At 6 months, 90 % of patients achieved remission. Disease control and remission were achieved at median times of 1 and 3.7 months, respectively. There was a 67 % relapse rate during an average follow-up of 22 months. Global CD4+ T cell numbers and function were preserved 3 months after rituximab. A single cycle of RA dosage rituximab with concomitant immunosuppression is effective in pemphigus. We did not find an effect on total CD4+ T cell numbers or function 3 months after treatment.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Autoantibodies/blood , B-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/immunology , Pemphigus/drug therapy , Adult , Aged , Antigens, CD20/blood , Antineoplastic Agents/therapeutic use , CD4 Lymphocyte Count , Female , Humans , Male , Middle Aged , Prospective Studies , Recurrence , Rituximab , Treatment Outcome
3.
Vaccine ; 25(6): 1071-5, 2007 Jan 22.
Article in English | MEDLINE | ID: mdl-17052814

ABSTRACT

A retrospective study was conducted to verify the possibility that people immunized with pneumococcal vaccine (PV) show lower morbidity not only for pneumonia but also for influenza. A total of 450 individuals were enrolled between 1999 and 2003 and allocated to one of the following groups: (A) not vaccinated; (B) immunized with PV during 1999; (C) immunized with anti-influenza vaccine (Flu-V) each year; and (D) immunized with PV once in 1999 and Flu-V every consecutive year. People from group B showed significantly lower percentage of influenza-related diseases during the year 2000 in comparison with those from group A (p<0.01), whereas in the course of 2001 the morbidity of patients from group B was lower compared with the other groups (p<0.01). The results point to a way to decrease the morbidity of influenza-related diseases by immunization with PV only, at least for 2-3 years, avoiding Flu-V administration and permitting considerable saving for health care providers. Therefore, it is concluded that PV can reduce the morbidity of influenza at a greater rate than the Flu-V.


Subject(s)
Influenza, Human/epidemiology , Influenza, Human/therapy , Pneumococcal Vaccines/administration & dosage , Aged , Aged, 80 and over , Female , Humans , Influenza Vaccines/administration & dosage , Influenza Vaccines/economics , Influenza Vaccines/immunology , Influenza, Human/immunology , Male , Middle Aged , Morbidity , Pneumococcal Vaccines/economics , Pneumococcal Vaccines/immunology , Retrospective Studies
4.
J Clin Pharm Ther ; 29(5): 437-41, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15482387

ABSTRACT

CONTEXT: Trimethoprim-sulfamethoxazole (TMP-SMX) and nitrofurantoin were until recently the two drugs recommended in clinical guidelines in Israel for empiric treatment of uncomplicated urinary tract infection (UTI) in women. OBJECTIVES: The objective of this study is to evaluate the economic impact of physician non-adherence to these recommendations. DESIGN SETTING AND PATIENTS: Data were derived from the electronic patient records of the Leumit Health Fund. Cases of women aged 18 to 75 with a diagnosis of acute cystitis or UTI that were empirically treated with antibiotics from January 2001 to June 2002 were identified. The final sample comprised 7738 physician-patient encounters. The proportion of cases treated with each individual drug was calculated, and the excess expenditure because of non-adherence to guidelines from the perspective of the Health Maintenance Organization (HMO) was evaluated using 5 days of therapy with nitrofurantoin as the reference treatment. RESULTS: TMP-SMX was the most frequently prescribed drug (25.81%), followed by nitrofurantoin (14.71%) representing a 40.52% rate of adherence to the guidelines. Drugs from the fluoroquinolone family were prescribed in 22.82% of cases. Cost of treatment in approximately 70% of the cases exceeded the expected cost of the guideline therapy. CONCLUSIONS: Suboptimal adherence to the guidelines resulted in a significant and avoidable waste of the health plan's resources in both drugs and money.


Subject(s)
Anti-Infective Agents, Urinary/economics , Anti-Infective Agents, Urinary/therapeutic use , Guideline Adherence , Nitrofurantoin/economics , Nitrofurantoin/therapeutic use , Practice Patterns, Physicians'/statistics & numerical data , Trimethoprim, Sulfamethoxazole Drug Combination/economics , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Urinary Tract Infections/drug therapy , Urinary Tract Infections/economics , Adolescent , Adult , Aged , Cost-Benefit Analysis , Costs and Cost Analysis , Female , Health Care Costs/statistics & numerical data , Health Maintenance Organizations/statistics & numerical data , Humans , Medical Records Systems, Computerized/statistics & numerical data , Middle Aged , Practice Guidelines as Topic , Practice Patterns, Physicians'/economics , Retrospective Studies
5.
Am J Clin Pathol ; 97(5): 663-4, 1992 May.
Article in English | MEDLINE | ID: mdl-1575211

ABSTRACT

Cerebrospinal fluid from a 42-year-old man with acquired immune deficiency syndrome was processed in a Coulter S-plus counter and found to contain "4.8 x 10(9) leukocytes/L:56.1% granulocytes and 37.7% lymphocytes." Direct examination of the same specimen in a counting chamber revealed that the leukocytes were cells of Cryptococcus neoformans. Coulter analysis of cerebrospinal fluid may be inappropriate, particularly when yeast infection is a probable diagnosis.


Subject(s)
Blood Cell Count/instrumentation , Cryptococcus/isolation & purification , Leukocytes/pathology , Meningitis, Cryptococcal/microbiology , Acquired Immunodeficiency Syndrome/cerebrospinal fluid , Adult , Cerebrospinal Fluid/cytology , Cerebrospinal Fluid/microbiology , Diagnostic Errors , Humans , Male , Meningitis, Cryptococcal/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...